Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > University of Virginia Cancer Center and Keystone Nano Announce Start of Clinical Testing of Ceramide Nanoliposome for Treatment of Solid Tumors

Abstract:
University of Virginia Cancer Center and Keystone Nano, Inc. announce that clinical testing has been initiated at UVA on a new potential cancer therapy. The study is a Phase I clinical trial to assess Ceramide NanoLiposome in the treatment of solid tumors.

University of Virginia Cancer Center and Keystone Nano Announce Start of Clinical Testing of Ceramide Nanoliposome for Treatment of Solid Tumors

Charlottesville, VA and State College, PA | Posted on August 28th, 2017

Dr. Mark Kester, Keystone Nano’s Chief Medical Officer, Director of UVA’s NanoSTAR program and the original developer of Ceramide NanoLiposome, remarked: “We are excited to investigate the effectiveness of this potential therapy in patients with solid tumors.” Mr. Jeff Davidson, Keystone Nano’s CEO remarked: “Our company is pleased to be working with the University of Virginia Cancer Center and look forward to the testing of this new therapy.”
Ceramide is a biologically active lipid that is being examined as a potential treatment for liver cancer, as well as in breast cancer, leukemia and pancreatic cancer. Ceramide NanoLiposome seeks to kill cancer cells while leaving normal cells alone, providing treatment without undue toxicity.

The Phase I portion of the trial will recruit patients with solid tumors to examine dosing and safety. The Phase II component of the trial is expected to focus on Liver Cancer, which kills approximately 27,000 people in the United States and 700,000 worldwide each year. There is currently no effective therapy for this disease. Keystone Nano was recently awarded orphan drug status for the treatment of liver cancer with ceramides in the United States.

####

About Keystone Nano
Based in State College KN is working at the interface between nanotechnology and medicine. In addition to developing Ceramide NanoLiposome, the company is working on additional products using NanoJackets for RNA delivery.

For more information, please click here

Contacts:
eff Sirianni
Managing Member
Monarch Solutions, LLC
Ashburn, VA 20147
Mobile: (703) 728.6837
www.Monarchsls.com

Copyright © Keystone Nano

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

High-performance self-assembled catalyst for SOFC October 12th, 2018

Cancer

Nano Pharmaceutical Developed to Target Cancer Cells October 10th, 2018

Scientists use nanoparticles to improve chemotherapy response, boost anti-tumor immunity: U of T scientists use nanoparticles to improve chemotherapy response and boost anti-tumor immunity in breast cancer October 2nd, 2018

Rice U. lab probes molecular limit of plasmonics: Optical effect detailed in organic molecules with fewer than 50 atoms September 5th, 2018

Polymer antibodies efficiently target and eliminate cancer cells August 27th, 2018

Govt.-Legislation/Regulation/Funding/Policy

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

High-performance self-assembled catalyst for SOFC October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

Nanomedicine

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

Announcements

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

TUBALL single wall carbon nanotubes: No ecotoxicity found, unlike other carbon nanotubes October 12th, 2018

Nanobiotechnology

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project